Reduction in stroke with gemfibrozil in men with coronary heart disease and low HDL cholesterol the veterans affairs HDL intervention trial (VA-HIT)

Circulation

Volumn 103, Issue 23, 2001, Pages 2828-2833

  Rubins, Hanna Bloomfield ^a   Davenport, John ^b   Babikian, Viken ^a   Brass, Lawrence M ^d   Collins, Dorothea ^e   Wexler, Laura ^a   Wagner, Stephen ^f   Papademetriou, Vassilios ^g   Rutan, Gale ^h,i   Robins, Sander J ^c  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b PARK NICOLLET CLINIC   (United States)

^c BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

^e DEPARTMENT OF VETERANS AFFAIRS   (United States)

^f VETERANS AFFAIRS MEDICAL CENTER   (United States)

^g VETERANS AFFAIRS MEDICAL CENTER   (United States)

^h VETERANS AFFAIRS MEDICAL CENTER   (United States)

ⁱ RICHARD L ROUDEBUSH VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Cholesterol; Coronary disease; Gemfibrozil; Stroke

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG EFFECT; HUMAN; HYPOCHOLESTEROLEMIA; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK; STROKE; UNITED STATES;

EID: 0035849546     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.cir.103.23.2828     Document Type: Article

References (30)

1. High-density lipoprotein cholesterol and cardiovascular disease: Four prospective American studies
2. High-density lipoprotein cholesterol and risk of ischemic stroke mortality: A 21-year follow-up of 8586 men from the Israeli Ischemic Heart Disease Study
3. Influence of total cholesterol, high density lipoprotein cholesterol, and triglycerides on risk of cerebro-vascular disease: The Copenhagen City Heart Study
4. HDL-cholesterol, total cholesterol, and the risk of stroke in middle-aged British men
5. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol
6. Rationale and design of the Department of Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial (HIT) for secondary, prevention of coronary artery disease in men with low high-density lipoprotein cholesterol and desirable low-density lipoprotein cholesterol
7. The Veterans Affairs High-Density Lipoprotein Intervention Trial: Baseline characteristics of normocholesterolemic men with coronary artery disease and low levels of high-density lipoprotein cholesterol
8. Classification of subtype of acute ischemic stroke: Definitions for use in a multicenter clinical trial
9. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)
10. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels
11. Effect of HMGcoA reductase inhibitors on stroke: A meta-analysis of randomized, controlled trials
12. Stroke, statins, and cholesterol: A meta-analysis of randomized, placebo-controlled, double-blind trials with HMG-CoA reductase inhibitors
13. Cholesterol lowering with statin drags, risk of stroke, and total mortality: An overview of randomized trials
14. Reductase inhibitor monotherapy and stroke prevention
15. Pravastatin therapy and the risk of stroke
16. Clofibrate and niacin in coronary heart disease
17. Helsinki Heart Study: Primary prevention trial with gemfibrozil in middle-aged men with dyslipidemia
18. Prevention of the anglo-graphic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol
19. Echo-lucency of computerized ultrasound images of carotid atherosclerotic plaques are associated with increased levels of triglyceride-rich lipoproteins as well as increased plaque lipid content
20. Alimentary lipemia, postprandial triglyceride-rich lipoproteins, and common carotid intima-media thickness in healthy, middle-aged men
21. Exercise-induced vasomotion of angiographically normal and stenotic coronary arteries improves after cholesterol-lowering drug therapy with bezafibrate
22. Activation of human aortic smooth-muscle cells is inhibited by PPARα but not by PPARγ activators
23. Effects of fenofibrate on plasma cytokine concentrations in patients with atherosclerosis and hyperlipo-proteinemia IIb
24. PPARα activators inhibit cytokine-induced vascular cell adhesion molecule-I expression in human endothelial cells
25. Direct effects of gemfibrozil on the fibrinolytic system: Diminution of synthesis of plasminogen activator inhibitor type I
26. The effects of fibrates on lipoprotein and hemostatic coronary risk factors
27. Prospective study of markers of hemostatic function with risk of ischemic stroke
28. Hemostatic factors as predictors of ischemic heart disease and stroke in the Edinburgh artery study
29. Effect of simvastatin on ischemic signs and symptoms in the Scandinavian Simvastatin Survival Study (4S)
30. Reduction of stroke incidence after myocardial infarction with pravastatin: The Cholesterol and Recurrent Events (CARE) study